Acquisition of gender agreement in Lithuanian:exploring the effect of diminutive usage in an elicited production task

This study examines Lithuanian children's acquisition of gender agreement using an elicited production task. Lithuanian is a richly inflected Baltic language, with two genders and seven cases. Younger (N=24, mean 3;1, 2;5–3;8) and older (N=24, mean 6;3, 5;6–6;9) children were shown pictures of animals and asked to describe them after hearing the animal's name. Animal names differed with respect to familiarity (novel vs. familiar), derivational status (diminutive vs. simplex) and gender (masculine vs. feminine). Analyses of gender-agreement errors based on adjective and pronoun usage indicated that younger children made more errors than older children, with errors more prevalent for novel animal names. For novel animals, and for feminine nouns, children produced fewer errors with nouns introduced in diminutive form. These results complement findings from several Slavic languages (Russian, Serbian and Polish) that diminutives constitute a salient cluster of word forms that may provide an entry point for the child's acquisition of noun morphology

Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2

Enzymes that modify the epigenetic status of cells provide attractive targets for therapy in various diseases. The therapeutic development of epigenetic modulators, however, has been largely limited to direct targeting of catalytic active site conserved across multiple members of an enzyme family, which complicates mechanistic studies and drug development. Class IIa histone deacetylases (HDACs) are a group of epigenetic enzymes that depends on interaction with Myocyte Enhancer Factor-2 (MEF2) for their recruitment to specific genomic loci. Targeting this interaction presents an alternative approach to inhibiting this class of HDACs. We have used structural and functional approaches to identify and characterize a group of small molecules that indirectly target class IIa HDACs by blocking their interaction with MEF2 on DNA.Weused X-ray crystallography and 19F NMRto show that these compounds directly bind to MEF2. We have also shown that the small molecules blocked the recruitment of class IIa HDACs to MEF2-targeted genes to enhance the expression of those targets. These compounds can be used as tools to study MEF2 and class IIa HDACs in vivo and as leads for drug development

Epigenetic modulators as therapeutic targets in prostate cancer

Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.info:eu-repo/semantics/publishedVersio